Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| prostate cancer genetic testing |
|
PHG Foundation | Newsletter Ethical issues in the forensic use of bioinformation, HGC advocates legal ban on 'genetic discrimination', Gene expression test for prostate cancer InteliHealth: Decision Guide: Breast And Ovarian Cancer. Decision Guide, Is genetic testing right for you? Consider the many factors and issues with our interactive tool. Monthly Summaries of Nursing Research In recent years, 6 prostate cancer gene regions have been identified, and a test for genetic susceptibility to prostate cancer may soon be available. Assessing Patient Values Towards Prostate Cancer Genetic Screening The survey will evaluate those relevant values, social factors, attitudes, and beliefs that are relevant to genetic screening for prostate cancer risk. A Genetics Perspective on Prostate Cancer Attitudes towards screening and genetic testing among men with a family history of prostate cancer have also been explored. In one study from Sweden of 69 DNA Test To Detect Prostate Cancer Risk usrbingeekâ™s musings Prostate cancer is strongly associated with increasing age, with 60 per cent of cases occurring in men over the age of 70. But there are also strong genetic Men's values-based factors on prostate cancer risk genetic testing While a definitive genetic test for Hereditary Prostate Cancer (HPC) is not yet available, future HPC risk testing may become available. How men view genetic testing for prostate cancer risk: findings inheritance of prostate cancer, screening, and genetic test- regarding genetic testing for hereditary prostate cancer. risk. Urology 2000: 55: 46â“50. IngentaConnect Attitudes and beliefs concerning prostate cancer Attitudes and beliefs concerning prostate cancer genetic screening intention of men to undergo or defer genetic testing for prostate cancer risk using a IngentaConnect Attitudes and beliefs concerning prostate cancer Attitudes and beliefs concerning prostate cancer genetic screening conducted to rank key values and beliefs about genetic testing for prostate cancer BBC NEWS | Health | Genetic test for prostate cancer A genetic test which may improve accurate diagnosis of prostate cancer is launched in the UK. Assessing Patient Values Towards Prostate Cancer Genetic Screening. The project, "Assessing Patient Values Towards Prostate Cancer Genetic Screening", has begun to determine the values, beliefs, and attitudes that influence Genetic test for prostate cancer - Times Online A genetic test for prostate cancer, which should transform the way the disease is detected and monitored, is now available in Britain. First genetic test for prostate cancer - Times Online THE first genetic test for prostate cancer, which kills 10000 men every year in Britain, will be launched here this week. The Genetics of Prostate Cancer - PLWC However, more research is needed to better understand how these genes impact the risk of prostate cancer before genetic testing becomes available. Genetics of Prostate Cancer - National Cancer Institute 1,2 Genetic testing for prostate cancer susceptibility is not available outside of the context of a research study. Families with prostate cancer can be Bostwick Labs Announces PCA3Plusâ„¢ Genetic Test for Prostate Cancer PCA3Plus(TM, a urine-based genetic test for prostate cancer from Bostwick Laboratories, Inc., is now available. Cancer Genetics - National Cancer Institute Genetics of Prostate Cancer (PDQ®) health professional . Policy. ASCO Policy Statement on Genetic Testing for Cancer Susceptibility · ASHG/ACMG REPORT. Bostwick Laboratories Announces uPM3(â„¢ Test, First Genetic Test Update: PCA3Plusâ„¢ the Next Generation Genetic Test for Prostate Cancer Risk May 2006. For more information about Bostwick Laboratories or uPM3(TM), |
| prostate cancer genetic testing |
|
infection of the prostate gland london massage prostate prostate cancer blood semen immunohistochemistry prostate |